FDA approves expanded use of Emergent BioSolution's anthrax vaccine

November 24, 2015 2:09 PM

16 0

FDA approves expanded use of Emergent BioSolution's anthrax vaccine

The U.S. Food and Drug Administration approved to expand the use of Emergent BioSolutions Inc's anthrax vaccine to prevent suspected or confirmed exposure to the bacterium that causes the disease.

The FDA approved the vaccine, BioThrax, for use in patients who are between 18-65 years of age in conjunction with antibiotic treatment.

Read more

To category page

Loading...